BiotechTube

Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment C

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Food Effects on Pharmacokinetics

Conditions

Food Effects on Pharmacokinetics

Trial Timeline

Aug 16, 2018 → Sep 13, 2018

NCT ID
NCT03647202

About Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment C

Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment C is a phase 1 stage product being developed by Daiichi Sankyo for Food Effects on Pharmacokinetics. The current trial status is completed. This product is registered under clinical trial identifier NCT03647202. Target conditions include Food Effects on Pharmacokinetics.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03647202Phase 1Completed

Competing Products

17 competing products in Food Effects on Pharmacokinetics

See all competitors
ProductCompanyStageHype Score
E7386EisaiPhase 1
33
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solutionAstraZenecaPhase 1
33
AcalabrutinibAstraZenecaPhase 2
52
esomeprazole/ASA Fixed Dose Combination (FDC)AstraZenecaPhase 1
33
Ligelizumab 120 mg + Ligelizumab 240 mgNovartisPhase 3
77
OmalizumabNovartisApproved
85
Omalizumab InjectionRocheApproved
85
Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PESanofiPhase 1
32
DupilumabRegeneron PharmaceuticalsPre-clinical
22
linvoseltamab + dupilumabRegeneron PharmaceuticalsPhase 1
32
DupilumabRegeneron PharmaceuticalsPhase 2
51
Sativex + Sativex + Sativex + SativexJazz PharmaceuticalsPhase 1
30
fruquintinibHUTCHMEDPhase 1
28
VolitinibHUTCHMEDPhase 1
28
Viaskin Milk 150 mcg + Viaskin Milk 300 mcg + Viaskin Milk 500 mcg + Viaskin PlaceboDBV TechnologiesPhase 1/2
36
AZD1722 salt tablet + AZD1722 free base tablet + AZD1722 free base tablet + OmeprazoleArdelyxPhase 1
28
E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3Allergy TherapeuticsPhase 1
28

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85